Hematological and Oncological Emergencies

  • Hartmut Bertz
  • Hartmut Henß
  • Beate Lubrich


Disseminate Intravascular Coagulation Fresh Freeze Plasma Spinal Cord Compression Tumor Lysis Syndrome Cytostatic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–53PubMedCrossRefGoogle Scholar
  2. 2.
    Bertz H, Auner HW, Weissinger F et al. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation: guidelines of the AGIHO/DGHO. Ann Hematol 2003;82(suppl 2):S167–74PubMedCrossRefGoogle Scholar
  3. 3.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences and new directions for its management. Cancer 2004;100:228–37PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Recommendations for the application. Ann Oncol 2007;18(Suppl.2):ii89–91CrossRefGoogle Scholar
  5. 5.
    Penack O, Beinert T, Buchheidt D et al. Management of sepsis in neutropenia: guidelines of the AGIHO/DGHO. Ann Hematol 2006;85:424–33PubMedCrossRefGoogle Scholar
  6. 6.
    Sipsas NV, Bodey GP, Kostoyiannis DP. Perspectives for the management of febrile neutropenic patients. Cancer 2005;103:1103–13PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TJ, Khatcheressian J, Lyman GJ et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205PubMedCrossRefGoogle Scholar
  8. 1. NCCNGoogle Scholar
  9. 1.
    Aurora R, Milite F, Vander Els NJ. Respiratory emergencies. Semin Oncol 2000;27:256–69PubMedGoogle Scholar
  10. 2.
    Kanani RS, Drachmann DE. Malignant obstruction of the superior vena cava. N Engl J Med 2006;354:e7PubMedCrossRefGoogle Scholar
  11. 3.
    Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001;CD001316Google Scholar
  12. 4.
    Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007;356:1862–9PubMedCrossRefGoogle Scholar
  13. 1. E-medicineGoogle Scholar
  14. 2.
cardiopulmonary/patient NCI Cancer TopicsGoogle Scholar
  15. 3. Family PracticeGoogle Scholar
  16. 1.
    Bagley CA, Gokaslan ZL. Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus 2004;16:e3PubMedCrossRefGoogle Scholar
  17. 2.
    Byrne T. Spinal cord compression from epidural metastases. N Engl J Med 1992;327:614–7PubMedGoogle Scholar
  18. 3.
    Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence based guideline. J Clin Oncol 1998;16:1613–24PubMedGoogle Scholar
  19. 4.
    Maranzano E, Bellavita R, Rossi R et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005;23:3358–65PubMedCrossRefGoogle Scholar
  20. 5.
    Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin Oncol 2000;27:311–21PubMedGoogle Scholar
  21. 1. Cauda Equina PortalGoogle Scholar
  22. 2. E-medicineGoogle Scholar
  23. 3. Merck ManualGoogle Scholar
  24. 1.
    Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000;27:244–55PubMedGoogle Scholar
  25. 2.
    Little WC, Freeman GL. Pericardial disease. Circulation 2006;113:1622–32PubMedCrossRefGoogle Scholar
  26. 3.
    Martinoni A, Cipolla CM, Civelli M et al. Intrapericardial treatment of neoplastic pericardial effusions. Herz 2000;25:787–93PubMedCrossRefGoogle Scholar
  27. 4.
    Retter AS. Pericardial disease in the oncology patient. Heart Dis 2002;4:387–91PubMedCrossRefGoogle Scholar
  28. 5.
    Soler-Soler J, Sagrista-Sauleda J, Permanyer-Miralda G. Management of pericardial effusion. Heart 2001;86:235–40PubMedCrossRefGoogle Scholar
  29. 6.
    Spodick DH. Acute cardiac tamponade. N Engl J Med 2003;349:684–90PubMedCrossRefGoogle Scholar
  30. 1. E-medicineGoogle Scholar
  31. 2. E-medicineGoogle Scholar
  32. 3. MedlinePlusGoogle Scholar
  33. 1.
    Bajorunas DR. Clinical manifestations of cancer-related hypercalcemia. Semin Oncol 1990;17:16–20PubMedGoogle Scholar
  34. 2.
    Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322–34PubMedGoogle Scholar
  35. 3.
    Perry CM, Figgitt DP. Zoledronic acid. Drugs 2004;64:1197–211PubMedCrossRefGoogle Scholar
  36. 4.
    Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373–9PubMedCrossRefGoogle Scholar
  37. 1.
hypercalcemia/patient NCI Cancer TopicsGoogle Scholar
  38. 2. 260.htm E-medicineGoogle Scholar
  39. 1.
    Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Hematol 2004;127:3–11CrossRefGoogle Scholar
  40. 2.
    Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition and alternative treatment approaches. Clin Adv Hematol Oncol 2005;3:54–61PubMedGoogle Scholar
  41. 3.
    Nicolin G. Emergencies and their management. Eur J Cancer 2002;38:1365–77PubMedCrossRefGoogle Scholar
  42. 1. E-medicineGoogle Scholar
  43. 2. InfoportalGoogle Scholar
  44. 1.
    British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006;135:634–41CrossRefGoogle Scholar
  45. 2.
    Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol 2005;3:102–10Google Scholar
  46. 3.
    Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301–11PubMedCrossRefGoogle Scholar
  47. 4.
    Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004;9:561–70PubMedCrossRefGoogle Scholar
  48. 5.
    Reimann T, Butts CA. Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature. Can J Gastroenterol 2001;15:67–71Google Scholar
  49. 1. Scholar
  50. 2. Scholar
  51. 1.
    Davenport DD. Pathophysiology of hemolytic transfusion reactions. Semin Hematol 2005;42:165–9PubMedCrossRefGoogle Scholar
  52. 2.
    Dzik WH. New technology for transfusion safety. Br J Haematol 2006;136:181–90PubMedCrossRefGoogle Scholar
  53. 3.
    Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections 2003. Curr Opin Hematol 2003;10:412–8PubMedCrossRefGoogle Scholar
  54. 4.
    Popovsky MA (ed). Transfusion Reactions, 2nd edn. AABB Press, Bethesda, USA, 2001Google Scholar
  55. 5.
    Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002;117:257–87CrossRefGoogle Scholar
  56. 6.
    Sillmann CC, Ambrusi DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266–73CrossRefGoogle Scholar
  57. 1. E-medicineGoogle Scholar
  58. 2. Medline PlusGoogle Scholar
  59. 3. Puget Sound Blood CtrGoogle Scholar
  60. 4. MD Anderson, Transfusion ReactionsGoogle Scholar
  61. 1.
    Davies AG, Russell WC, Thompson JP. Extravasation and tissue necrosis due to central line infusions. Anaesthesia 2003;58:820–1PubMedCrossRefGoogle Scholar
  62. 2.
    Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858–62PubMedCrossRefGoogle Scholar
  63. 3.
    Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006;33:139–42PubMedCrossRefGoogle Scholar
  64. 4.
    Kurul SP, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 2002;3:684–92PubMedCrossRefGoogle Scholar
  65. 5.
    Napoli P, Corradino B, Badalamenti G et al. Surgical treatment of extravasation injuries. J Surg Oncol 2005;91:264–8PubMedCrossRefGoogle Scholar
  66. 6.
    Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol 2003;14(suppl 3):iii26–30PubMedGoogle Scholar
  67. 7.
    Schulmeister L. Managing vesicant extravasations. Oncologist 2008;13:284–8PubMedCrossRefGoogle Scholar
  68. 1. Natl Extravasation InfoGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Hartmut Bertz
    • 1
  • Hartmut Henß
    • 2
  • Beate Lubrich
    • 3
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Comprehensive Cancer Center FreiburgTumorzentrum Ludwig HeilmeyerFreiburgGermany
  3. 3.Hospital PharmacyUniversity Medical CenterFreiburgGermany

Personalised recommendations